Cost effectiveness analysis of immunotherapy in patients with grass pollen allergic rhinoconjunctivitis in Germany

References

• Togias AG. Systemic immunologic and inflammatory aspects of allergic rhinitis. J Allergy Clin Immunol 2000;106(5 Suppl):S247-50
   PubMed Web of Science ®Google Scholar
• Druce HM. Allergic and non-allergic rhinitis. In: Middleton EM Jr, Reed CE, Ellis EF, et al, eds. Allergy: principles and practice. 5th ed. St. Louis, Mo: Mosby Year Book, 1998. p 1005–16
   Google Scholar
• Augustin M, Herberger K, Hintzen S, et al. Prevalence of skin lesions and need for treatment in a cohort of 90,880 workers. Br J Dermatol 2011;165:865-73
   PubMed Web of Science ®Google Scholar
• Bousquet J, Khaltaev N, Cruz AA, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 Update (in collaboration with the World Health Organization, GA2LEN* and AllerGen). Allergy 2008;63(86 Suppl):S8-160
   PubMed Web of Science ®Google Scholar
• Shaaban R, Zureik M, Soussan D, et al. Rhinitis and onset of asthma: a longitudinal population-based study. Lancet 2008;372:1049-57
   PubMed Web of Science ®Google Scholar
• Leynaert B, Neukirch C, Liard R, et al. Quality of life in allergic rhinitis and asthma. A population-based study of young adults. Am J Respir Crit Care Med 2000;162:1391-96
   PubMed Web of Science ®Google Scholar
• Statistisches Bundesamt Deutschland. Gesundheitsbericht für Deutschland: Spezialbericht Allergien. Stuttgart: Metzler–Poeschel, 2000
   Google Scholar
• Schramm B, Ehlken B, Smala A, et al. Cost of illness of atopic asthma and seasonal allergic rhinitis Germany: 1-yr retrospective study. Eur Respir J 2003;21:116-22
   PubMed Web of Science ®Google Scholar
• EFA; European Federation of Allergy and Airway Diseases Patients Association. Results of the patient voice allergy survey. Impact of allergic rhinitis in Europe. Summary Report 2005
   Google Scholar
• Radulovic S, Calderon M, Wilson S, et al. Sublingual immunotherapy for allergic rhinitis: an updated Cochrane systematic review and meta-analysis. Allergy 2007;62(83 Suppl):263. Available from http://www.efanet.org/activities/publications_allergy.html
   Google Scholar
• Durham SR, Walker SM, Varga EM, et al. Long-term clinical efficacy of grass-pollen allergen specific immunotherapy. N Engl J Med 1999;34:468-75
   Google Scholar
• Valovirta E, Jacobsen L, Niggemann B, et al. A 3-year course of subcutaneous specific immunotherapy results in long-term prevention of asthma in children. Ten year follow-up on the PATstudy. J Allergy Clin Immunol 2006;117:721
   Google Scholar
• Marogna M, Spadolini I, Massolo A, et al. Long-lasting effects of sublingual immunotherapy according to its duration: a 15-year prospective study. J Allergy Clin Immunol 2010;126:969-75
   PubMed Web of Science ®Google Scholar
• Mosbech H, Osterballe O. Does the effect of immunotherapy last after termination of treatment? Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 1999;341:523-9
   Google Scholar
• Stallergenes. Fachinformation OA Gräser. 2007. http://portal.dimdi.de/amispb/ doc/pei/Web/2604176-spcde-20100301.pdf. Accessed February 2011
   Google Scholar
• Didier A, Worm M, Horak F, et al. Sustained 3-year efficacy of pre- and coseasonal 5-grass-pollen sublingual immunotherapy tablets in patients with grass pollen-induced rhinoconjunctivitis. J Allergy Clin Immunol 2011;128:559-66
   PubMed Web of Science ®Google Scholar
• Stiftung Deutschrer polleninformationdienst. Gesamtdeutscher Pollenflugkalender. 2011. http://www.pollenstiftung.de/. Accessed March 2011
   Google Scholar
• Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009]. The Cochrane Collaboration, 2009. Available from www.cochrane-handbook.org
   Google Scholar
• Di Bona D, Plaia A, Scafidi V, et al. Efficacy of sublingual immunotherapy with grass allergens for seasonal allergic rhinitis: a systematic review and meta-analysis. Allergy Clin Immunol 2010;126:558-66
   Google Scholar
• Didier A, Malling HJ, Worm M, et al. Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. J Allergy Clin Immunol 2007;120:1338-45
   PubMed Web of Science ®Google Scholar
• Wahn U, Tabar A, Kuna P, et al. Efficacy and safety of 5-grass-pollen sublingual immunotherapy tablets in pediatric allergic rhinoconjunctivitis. J Allergy Clin Immunol 2009;123:160-6
   PubMed Web of Science ®Google Scholar
• Dahl R, Kapp A, Colombo G, et al. Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006;118:434-40
   PubMed Web of Science ®Google Scholar
• Sieber J, De Geest S, Shah-Hosseini K, et al. Medication persistence with long-term, specific grass pollen immunotherapy measured by prescription renewal rates. Current Medical Research & Opinion 2011;27:855-61
   PubMed Web of Science ®Google Scholar
• Novembre E, Galli E, Landi F, et al. Co-seasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol 2004;114:851-7
   PubMed Web of Science ®Google Scholar
• Möller C, Dreborg S, Ferdousi HA, et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol 2002;109:251-6
   PubMed Web of Science ®Google Scholar
• Statistisches Bundesamt Deutschland, Wiesbaden 2010. Bevölkerung und Erwerbstätigkeit. Sterbetafel Deutschland. http://www.destatis.de. Accessed February 2011
   Google Scholar
• Huovinen E, Kaprio J, Vesterinen E, et al. Mortality of adults with asthma: a prospective cohort study. Thorax 1997;52:49-54
   PubMed Web of Science ®Google Scholar
• Revicki DA, Leidy NK, Brennan-Diemer F, et al. Development and preliminary validation of the multiattribute Rhinitis Symptom Utility Index. Qual Life Res 1998;7:693-702
   PubMed Web of Science ®Google Scholar
• Brüggenjürgen B, Reinhold T, Brehler R, et al. Cost-effectiveness of specific subcutaneous immunotherapy in patients with allergic rhinitis and allergic asthma. Ann Allergy Asthma Immunol 2008;101:316-24
   PubMed Web of Science ®Google Scholar
• Bernert S, Fernández A, Haro JM, et al. Comparison of different valuation methods for population health status measured by the EQ-5D in three European Countries. Value Health 2009;12:750-8
   PubMed Web of Science ®Google Scholar
• ALK-Abelló. Fachinformation GRZ. 2011. http://portal.dimdi.de/amispb/doc/pei/Web/2603749-spcde-20110501.pdf. Accessed February 2011
   Google Scholar
• ALK-Abelló. ALK-depot SQ Gebrauchs-und Fachinformation August 2008. http://www.alk-abello.com/DE/Apotheken/Produkte/ALK-SQ/Lists/alksq/GIFI%20ALK-depot%20SQ%20Gr%C3%A4serpollen.pdf. Accessed February 2011
   Google Scholar
• Lauer-Fischer GmbH. Lauer-Taxe mit Apotheken-Ein- und Verkaufspreisen. http://www2.lauer-fischer.de/produkte/arzneimitteldaten-online/webapor-lauer-taxe/. Accessed April 2011
   Google Scholar
• Bachert C, Vestenbæk U, Christensen J, et al. Cost-effectiveness of grass allergen tablet (GRZ s) for the prevention of seasonal grass pollen induced rhinoconjunctivitis -- a Northern European perspective. Clin Exp Allergy 2007;37:772-9
   PubMed Web of Science ®Google Scholar
• Kassenarztliche Vereinigung Nordrhein. Regelleistungsvolumen und qualifikationsgebundene Zusatzvolumen. 2011. http://www.kvno.de/. Accessed April 2011
   Google Scholar
• Kassenarztliche Bundesvereinigung. EBM -- Einheitlicher Bewertungsmaßstab. www.kbv.de. Accessed April 2011. Stand: 1. Quartal 2011
   Google Scholar
• Gebührenordnung für Ärzte (GOÄ) online. 2011. http://www.e-bis.de/. Accessed April 2011
   Google Scholar
• Vita D, Caminiti L, Ruggeri P, et al. Sublingual immunotherapy: adherence based on timing and monitoring control visits. Allergy 2010;65:662-9
   PubMedGoogle Scholar
• Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). General methods for the assessment of the relation of benefits to costs. Version 1.0 – 19/11/2009 Germany
   Google Scholar
• Canonica GW, Poulsen PB, Vestenbæk U. Cost-effectiveness of GRZ s for prevention of grass pollen induced rhinoconjunctivitis in Southern Europe. Respir Med 2007;101:1885-94
   PubMed Web of Science ®Google Scholar
• Nasser S, Vestenbæk U, Beriot-Mathiot A, et al. Cost-effectiveness of specific immunotherapy with GRZ in allergic rhinitis co-existing with asthma. Allergy 2008;63:1624-29
   PubMed Web of Science ®Google Scholar
• Keiding H, Jørgensen KP. A cost-effectiveness analysis of immunotherapy with SQ allergen extract for patients with seasonal allergic rhinoconjunctivitis in selected European countries. Curr Med Res Opin 2007;23:1113-20
   PubMed Web of Science ®Google Scholar
• Lüderitz-Püchel U, Keller-Stanislawski B, Haustein D. Neubewertung des Risikos von Test- und Therapieallergenen. Eine Analyse der UAW–Meldungen von 1991 bis 2000. Bundesgesundheitsbl-Gesundheitsforsch-Gesundheitsschutz 2001;44:709-18
   Google Scholar